Viking is making really solid pipeline progress and possesses a unique dual agonist approach in the obesity drugs market.

Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by ...

In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million as research and development spending accelerated, while confirming that its Phase 3 VANQUISH-1 and ...

Raymond James reiterated a 'Strong Buy' rating and $118 price target, implying a 258% upside ahead of earnings. ・Consensus estimates expect a GAAP loss per share of $1.03, wider than last year’s $0.4 ...

Q1 2026. Management View. Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabl ...

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least ...

The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy. ・The company said enrollment has been completed across both Phase 3 Vanquish ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...